628 related articles for article (PubMed ID: 32192453)
41. Pharmacogenetics in diffuse large B-cell lymphoma treated with R-CHOP: Still an unmet challenge.
Lavacchi D; Landini I; Perrone G; Roviello G; Mini E; Nobili S
Pharmacol Ther; 2022 Jan; 229():107924. PubMed ID: 34175369
[TBL] [Abstract][Full Text] [Related]
42. Global microRNA expression profiling uncovers molecular markers for classification and prognosis in aggressive B-cell lymphoma.
Iqbal J; Shen Y; Huang X; Liu Y; Wake L; Liu C; Deffenbacher K; Lachel CM; Wang C; Rohr J; Guo S; Smith LM; Wright G; Bhagavathi S; Dybkaer K; Fu K; Greiner TC; Vose JM; Jaffe E; Rimsza L; Rosenwald A; Ott G; Delabie J; Campo E; Braziel RM; Cook JR; Tubbs RR; Armitage JO; Weisenburger DD; Staudt LM; Gascoyne RD; McKeithan TW; Chan WC
Blood; 2015 Feb; 125(7):1137-45. PubMed ID: 25498913
[TBL] [Abstract][Full Text] [Related]
43. High concordance of gene expression profiling-correlated immunohistochemistry algorithms in diffuse large B-cell lymphoma, not otherwise specified.
Hwang HS; Park CS; Yoon DH; Suh C; Huh J
Am J Surg Pathol; 2014 Aug; 38(8):1046-57. PubMed ID: 24705314
[TBL] [Abstract][Full Text] [Related]
44. Short-term efficacy of rituximab-CHOP and CHOP regimens on two subtypes of diffuse large B-cell lymphoma.
Xia Y; Li ZM; Shi YX; Xia ZJ; Jiang WQ; Huang HQ
Ai Zheng; 2009 Feb; 28(2):146-9. PubMed ID: 19550126
[TBL] [Abstract][Full Text] [Related]
45. Interim positron emission tomography scan associated with international prognostic index and germinal center B cell-like signature as prognostic index in diffuse large B-cell lymphoma.
Lanic H; Mareschal S; Mechken F; Picquenot JM; Cornic M; Maingonnat C; Bertrand P; Clatot F; Bohers E; Stamatoullas A; Leprêtre S; Rainville V; Ruminy P; Bastard C; Tilly H; Becker S; Vera P; Jardin F
Leuk Lymphoma; 2012 Jan; 53(1):34-42. PubMed ID: 21806349
[TBL] [Abstract][Full Text] [Related]
46. Dysregulated CXCR4 expression promotes lymphoma cell survival and independently predicts disease progression in germinal center B-cell-like diffuse large B-cell lymphoma.
Chen J; Xu-Monette ZY; Deng L; Shen Q; Manyam GC; Martinez-Lopez A; Zhang L; Montes-Moreno S; Visco C; Tzankov A; Yin L; Dybkaer K; Chiu A; Orazi A; Zu Y; Bhagat G; Richards KL; Hsi ED; Choi WW; van Krieken JH; Huh J; Ponzoni M; Ferreri AJ; Zhao X; Møller MB; Farnen JP; Winter JN; Piris MA; Pham L; Young KH
Oncotarget; 2015 Mar; 6(8):5597-614. PubMed ID: 25704881
[TBL] [Abstract][Full Text] [Related]
47. High Ki-67 expression in diffuse large B-cell lymphoma patients with non-germinal center subtype indicates limited survival benefit from R-CHOP therapy.
Li ZM; Huang JJ; Xia Y; Zhu YJ; Zhao W; Wei WX; Jiang WQ; Lin TY; Huang HQ; Guan ZZ
Eur J Haematol; 2012 Jun; 88(6):510-7. PubMed ID: 22413767
[TBL] [Abstract][Full Text] [Related]
48. Cardiotoxicity with rituximab, cyclophosphamide, non-pegylated liposomal doxorubicin, vincristine and prednisolone compared to rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisolone in frontline treatment of patients with diffuse large B-cell lymphoma: A randomised phase-III study from the Austrian Cancer Drug Therapy Working Group [Arbeitsgemeinschaft Medikamentöse Tumortherapie AGMT](NHL-14).
Fridrik MA; Jaeger U; Petzer A; Willenbacher W; Keil F; Lang A; Andel J; Burgstaller S; Krieger O; Oberaigner W; Sihorsch K; Greil R
Eur J Cancer; 2016 May; 58():112-21. PubMed ID: 26990931
[TBL] [Abstract][Full Text] [Related]
49. Exosome-derived miRNAs as predictive biomarkers for diffuse large B-cell lymphoma chemotherapy resistance.
Feng Y; Zhong M; Zeng S; Wang L; Liu P; Xiao X; Liu Y
Epigenomics; 2019 Jan; 11(1):35-51. PubMed ID: 30211623
[TBL] [Abstract][Full Text] [Related]
50. Prognostic impact of p53 aberrations for R-CHOP-treated patients with diffuse large B-cell lymphoma.
Stefancikova L; Moulis M; Fabian P; Vasova I; Zedek F; Ravcukova B; Muzik J; Kuglik P; Vranova V; Falkova I; Hrabalkova R; Smardova J
Int J Oncol; 2011 Dec; 39(6):1413-20. PubMed ID: 21874232
[TBL] [Abstract][Full Text] [Related]
51. Rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisolone in patients with newly diagnosed diffuse large B-cell non-Hodgkin lymphoma: a phase 3 comparison of dose intensification with 14-day versus 21-day cycles.
Cunningham D; Hawkes EA; Jack A; Qian W; Smith P; Mouncey P; Pocock C; Ardeshna KM; Radford JA; McMillan A; Davies J; Turner D; Kruger A; Johnson P; Gambell J; Linch D
Lancet; 2013 May; 381(9880):1817-26. PubMed ID: 23615461
[TBL] [Abstract][Full Text] [Related]
52. Dose-Dense Rituximab-CHOP versus Standard Rituximab-CHOP in Newly Diagnosed Chinese Patients with Diffuse Large B-Cell Lymphoma: A Randomized, Multicenter, Open-Label Phase 3 Trial.
Li X; Huang H; Xu B; Guo H; Lin Y; Ye S; Yi J; Li W; Wu X; Wang W; Zhan H; Xie D; Peng J; Cao Y; Pu X; Guo C; Hong H; Wang Z; Fang X; Zhou Y; Lin S; Liu Q; Lin T
Cancer Res Treat; 2019 Jul; 51(3):919-932. PubMed ID: 30282447
[TBL] [Abstract][Full Text] [Related]
53. CD30 expression in de novo diffuse large B-cell lymphoma: a population-based study from British Columbia.
Slack GW; Steidl C; Sehn LH; Gascoyne RD
Br J Haematol; 2014 Dec; 167(5):608-17. PubMed ID: 25135752
[TBL] [Abstract][Full Text] [Related]
54. Protein kinase C-beta II expression in diffuse large B-cell lymphoma predicts for inferior outcome of anthracycline-based chemotherapy with and without rituximab.
Chaiwatanatorn K; Stamaratis G; Opeskin K; Firkin F; Nandurkar H
Leuk Lymphoma; 2009 Oct; 50(10):1666-75. PubMed ID: 19757311
[TBL] [Abstract][Full Text] [Related]
55. MicroRNA-23a expression in paraffin-embedded specimen correlates with overall survival of diffuse large B-cell lymphoma.
Wang WL; Yang C; Han XL; Wang R; Huang Y; Zi YM; Li JD
Med Oncol; 2014 Apr; 31(4):919. PubMed ID: 24659264
[TBL] [Abstract][Full Text] [Related]
56. Excellent outcomes and lack of prognostic impact of cell of origin for localized diffuse large B-cell lymphoma in the rituximab era.
Kumar A; Lunning MA; Zhang Z; Migliacci JC; Moskowitz CH; Zelenetz AD
Br J Haematol; 2015 Dec; 171(5):776-83. PubMed ID: 26456939
[TBL] [Abstract][Full Text] [Related]
57. Rituximab (MabThera) for aggressive non-Hodgkin's lymphoma: systematic review and economic evaluation.
Knight C; Hind D; Brewer N; Abbott V
Health Technol Assess; 2004 Sep; 8(37):iii, ix-xi, 1-82. PubMed ID: 15361313
[TBL] [Abstract][Full Text] [Related]
58. New prognosis score including absolute lymphocyte/monocyte ratio, red blood cell distribution width and beta-2 microglobulin in patients with diffuse large B-cell lymphoma treated with R-CHOP: Spanish Lymphoma Group Experience (GELTAMO).
Bento L; Díaz-López A; Barranco G; Martín-Moreno AM; Baile M; Martín A; Sancho JM; García O; Rodríguez M; Sánchez-Pina JM; Novelli S; Salar A; Bastos M; Rodríguez-Salazar MJ; González de Villambrosia S; Córdoba R; García-Recio M; Martínez-Serra J; Del Campo R; Luzardo H; García D; Hong A; Abrisqueta P; Sastre-Serra J; Roca P; Rodríguez J; Gutiérrez A;
Br J Haematol; 2020 Mar; 188(6):888-897. PubMed ID: 31782146
[TBL] [Abstract][Full Text] [Related]
59. [Correlation between Serum miR-34a Level and Thrombocytopenia after Chemotherapy in Patients with Diffuse Large B-Cell Lymphoma].
Zhang HL; Uticul A; Xu XW; Shi YW
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2022 Jun; 30(3):784-789. PubMed ID: 35680806
[TBL] [Abstract][Full Text] [Related]
60. Visceral adipose tissue is prognostic for survival of diffuse large B cell lymphoma treated with frontline R-CHOP.
Shin DY; Kim A; Byun BH; Moon H; Kim S; Ko YJ; Kim MJ; Lee HR; Kang HJ; Na II; Park S; Lee SS; Yang SH
Ann Hematol; 2016 Feb; 95(3):409-16. PubMed ID: 26658607
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
